Pfizer recalls Levoxyl 175 mcg levothyroxine sodium tablets over weaker-than-labeled strength
The tablets are subpotent, meaning they are weaker than labeled, after a stability test confirmed an out-of-specification assay result.
What to do
The notice does not give instructions. Read the official notice for details.
Note from Recalled Today: Don't stop taking a prescribed medicine before you talk to your pharmacist or doctor.
Recall details
- Product
- Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 100 tablet bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-01.; Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 1000-count bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-10
- Company
- Pfizer
- Hazard
- Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.
- Units
- 15,815 100-count bottles; 134 1000-count bottles
- Where sold
- US Nationwide and Puerto Rico
- FDA classification
- Class II · Ongoing
- Classified by FDA
- October 16, 2026
- Recall started
- September 29, 2026
- FDA enforcement report
- October 28, 2026
- Identifiers
- Codes: Lot # 24W06, Exp: 11/30/2026
- FDA recall number: D-0052-2027
- Codes: Lot # 24W07, Exp: 11/30/2026
- FDA recall number: D-0051-2027
The headline, summary and steps above are written in plain English from the official notice below. Identifiers are copied exactly as the agency published them. Always check the official notice before you act.
Official notice
The notice's own wording from FDA.
- Product
- Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 100 tablet bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-01. | Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 1000-count bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-10
- Reason for recall
- Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.
- Classification
- Class II (Ongoing)
- Distribution
- US Nationwide and Puerto Rico
- Quantity
- 15,815 100-count bottles; 134 1000-count bottles
Related recalls
Macleods Pharma recalls levothyroxine sodium 150 mcg tablets because they are weaker than labeled
The recalled 1000-count bottles of levothyroxine sodium tablets are subpotent, meaning they contain less of the medicine than they should, and 1315 bottles were sent out across the United States.
Macleods Pharma USA, INC · 1315 bottles
Major Pharmaceuticals recalls levothyroxine sodium tablets because they may be weaker than labeled
The recalled levothyroxine tablets (75 mcg, 88 mcg and 150 mcg strengths) are subpotent, meaning they contain less medicine than the label says.